» Articles » PMID: 37765011

Indole-Based and Cyclopentenylindole-Based Analogues Containing Fluorine Group As Potential F-Labeled Positron Emission Tomography (PET) G-Protein Coupled Receptor 44 (GPR44) Tracers

Overview
Publisher MDPI
Specialty Chemistry
Date 2023 Sep 28
PMID 37765011
Authors
Affiliations
Soon will be listed here.
Abstract

Recently, growing evidence of the relationship between G-protein coupled receptor 44 (GPR44) and the inflammation-cancer system has garnered tremendous interest, while the exact role of GPR44 has not been fully elucidated. Currently, there is a strong and urgent need for the development of non-invasive in vivo GPR44 positron emission tomography (PET) radiotracers that can be used to aid the exploration of the relationship between inflammation and tumor biologic behavior. Accordingly, the choosing and radiolabeling of existing GPR44 antagonists containing a fluorine group could serve as a viable method to accelerate PET tracers development for in vivo imaging to this purpose. The present study aims to evaluate published (2000-present) indole-based and cyclopentenyl-indole-based analogues of the GPR44 antagonist to guide the development of fluorine-18 labeled PET tracers that can accurately detect inflammatory processes. The selected analogues contained a crucial fluorine nuclide and were characterized for various properties including binding affinity, selectivity, and pharmacokinetic and metabolic profile. Overall, 26 compounds with favorable to strong binding properties were identified. This review highlights the potential of GPR44 analogues for the development of PET tracers to study inflammation and cancer development and ultimately guide the development of targeted clinical therapies.

Citing Articles

Monofluoromethylation of -Heterocyclic Compounds.

Moskalik M Int J Mol Sci. 2023; 24(24).

PMID: 38139426 PMC: 10744182. DOI: 10.3390/ijms242417593.


One-Step Automatic Radiosynthesis and Evaluation of [F]TM-30089 as GPR44 Radiotracer.

Peng J, Tang W, Rawson J, Miao L, Gonzalez N, Yin R Pharmaceuticals (Basel). 2023; 16(10).

PMID: 37895951 PMC: 10610095. DOI: 10.3390/ph16101480.

References
1.
Tawakol A, Ishai A, Takx R, Figueroa A, Ali A, Kaiser Y . Relation between resting amygdalar activity and cardiovascular events: a longitudinal and cohort study. Lancet. 2017; 389(10071):834-845. PMC: 7864285. DOI: 10.1016/S0140-6736(16)31714-7. View

2.
Pettipher R, Hansel T, Armer R . Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases. Nat Rev Drug Discov. 2007; 6(4):313-25. DOI: 10.1038/nrd2266. View

3.
Luker T, Bonnert R, Brough S, Cook A, Dickinson M, Dougall I . Substituted indole-1-acetic acids as potent and selective CRTh2 antagonists-discovery of AZD1981. Bioorg Med Chem Lett. 2011; 21(21):6288-92. DOI: 10.1016/j.bmcl.2011.08.124. View

4.
Qian F, Arner B, Kelly K, Annageldiyev C, Sharma A, Claxton D . Interleukin-4 treatment reduces leukemia burden in acute myeloid leukemia. FASEB J. 2022; 36(5):e22328. PMC: 9994642. DOI: 10.1096/fj.202200251R. View

5.
Murata T, Maehara T . Discovery of anti-inflammatory role of prostaglandin D. J Vet Med Sci. 2016; 78(11):1643-1647. PMC: 5138415. DOI: 10.1292/jvms.16-0347. View